NCT00180544View on ClinicalTrials.gov

Safety and Effectiveness Study of the HERCULINK 14 Stent to Treat Renal Artery Disease

PHASE3TerminatedINTERVENTIONAL
Enrollment

167

Participants

Timeline

Start Date

July 31, 2000

Primary Completion Date

August 31, 2004

Study Completion Date

August 31, 2004

Conditions
Renal Artery Obstruction
Interventions
DEVICE

Stenting: Renal Artery

Male and female patients, who meet study eligibility criteria, agree to participate in the trial, and sign an informed consent, will be enrolled in the study. A HERCULINK™ 14 Peripheral Stent will be used in the treatment of suboptimal post- procedural percutaneous transluminal angioplasty (PTA) atherosclerotic renal artery stenoses.

Trial Locations (1)

70121

Alton Ochsner Medical Foundation, New Orleans

Sponsors
All Listed Sponsors
lead

Abbott Medical Devices

INDUSTRY